RVTY Forensic analysis

Trading Setup & Entry Strategy

• >Entry Zone: Initiate a 30% position at $94.50 - $95.50. Add 40% on a confirmed breakout above $98.50 (post-consolidation), or add 30% on a test of the 200-day SMA at $94.40.
• >Stop Loss: $90.00 (Hard). Positioned just below the 50-day SMA ($90.17) to protect against a trend reversal.
• >Take Profit: Target 1: $103.50 (near Upper Bollinger Band); Target 2: $110.00 (psychological resistance).
• >Risk/Reward: Targeted 1:2.8.
• >Max Hold Time: 2 weeks (re-evaluate after June FOMC/macro volatility).

Executive Summary

Revvity (RVTY) is currently displaying a bullish structural setup, with price action holding above the 200-day SMA ($94.44). Q1 earnings beat expectations on organic growth, and recent FDA clearance for its total testosterone assay provides a fresh catalyst. Despite margin pressure from product mix and tariffs, management's cost-containment and focus on life science solutions suggest a stabilizing outlook. Analysis Date: 2026-05-20.

Recent Material Events & News

• >Earnings Performance: Q1 2026 reported revenue of $711.1M (up 7% YoY), driven by Diagnostics and Life Sciences.
• >Catalyst: FDA clearance (May 13, 2026) for a Total Testosterone Assay is a value-add for their diagnostic workflow, directly targeting clinical market share.
• >Strategic Shift: The market is digesting the China exit (Immunodiagnostics business), which is viewed as a 'portfolio reset' to improve long-term margins.

Financial Health & Forensics

• >Revenue Quality: Revenue mix is shifting towards high-margin services, though gross margins contracted by 200 bps to 54.5% due to product mix and tariffs.
• >Cash Flow: Operating cash flow is strong at $115.2M. The company continues to aggressively repurchase shares ($79M in Q1), signaling management's confidence in intrinsic value.
• >Balance Sheet: Debt remains manageable with the $1.5B revolver available; however, the $576M in 2026 notes maturity is a near-term item to monitor.

Technical Analysis & Trade Timing

• >Momentum: RSI at 55.03 is in a neutral-to-bullish expansion phase. The Bullish Cross (price above 200-day and 50-day SMA) indicates the primary trend is regaining control.
• >Reconciliation: While fundamentals show short-term margin headwinds, technicals show the stock is bottom-fishing in a recovery pattern. The Widowmaker Rule suggests we should not short here; the risk is to the upside as the stock recovers from the $90.00 support base.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days).
• >Position Size: 3% of portfolio.
• >Scaling: Buy at $95.00; add on move above $97.50.
• >Max Hold: 5 days. Exit if price closes below $94.00.

Investment Recommendation

BUY. Conviction Score: 7/10. The structural support at the 200-day SMA, combined with recent positive FDA regulatory news and ongoing share buybacks, provides a favorable risk-reward profile for a long position.

One-Liner Thesis: Revvity is executing a disciplined portfolio pivot while holding key technical support levels, making it a high-probability long candidate for institutional accumulation.